Antimalarial drugs: QT prolongation and cardiac arrhythmias

Area of Science:

• Pharmacology
• Cardiology
• Drug Safety

Background:

• Antimalarial drugs can cause significant cardiac side effects, ranging from heart rate changes to life-threatening arrhythmias like Torsade de Pointes (TdP).
• These cardiac events are primarily linked to the inhibition of ion channels, such as the human ether-a-go-go related gene (hERG) channel, disrupting cardiac repolarization.

Purpose of the Study:

• To review the current understanding of the mechanisms underlying QT prolongation and TdP induced by antimalarial drugs.
• To evaluate the cardiac safety profiles of existing antimalarial medications.

Main Methods:

• Review of existing literature on antimalarial drug cardiotoxicity.
• Analysis of cellular and organ-level electrophysiological changes associated with drug-induced arrhythmias.
• Examination of ion channel inhibition mechanisms.

Main Results:

• Certain antimalarial drugs, like halofantrine, are associated with excessive QT interval prolongation and TdP.
• Drugs like amodiaquine can cause milder heart rate alterations.
• Other antimalarials, such as co-artemether and sulfadoxine-pyrimethamine, exhibit fewer potent cardiac side effects.

Conclusions:

• A comprehensive cardiosafety strategy for novel antimalarial drugs is essential.
• This strategy should incorporate assays at multiple levels: ion channel, cellular, organ, and whole organism.
• Understanding drug-induced electrophysiological changes is critical for preventing severe cardiac events.